Change in disability after 26 or more weeks · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants who completed the study and did not restart IVIg therapy after IVIg withdrawal · people with CIDP
Interferon beta‐1a showed no clear difference in participants who completed the study and did not restart IVIg… compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Interferon beta‐1a showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Change in disability after 4 weeks disability grade change. Scale from: 0 to 10. · patients with Guillain‐Barré syndrome
1 finding from 1 review
Number improved by 1 or more disability grades after 4 weeks · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in number improved by 1 or more disability grades after 4 weeks compared with PE (moderate certainty).
1 finding from 1 review
Dead or disabled after 12 months (48 weeks) · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in dead or disabled after 12 months (48 weeks) compared with PE (low certainty).
1 finding from 1 review
Relapse or treatment‐related fluctuation · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in relapse or treatment‐related fluctuation compared with PE (low certainty).
1 finding from 1 review
Patients in whom treatment was discontinued · patients with Guillain‐Barré syndrome
IVIg leads to lower participants in whom treatment was discontinued compared with PE (high certainty).
1 finding from 1 review
Number of patients with adverse events attributed to treatment · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in number of participants with adverse events attributed to treatment compared with PE (moderate certainty).
1 finding from 1 review